Study of Erenumab (AMG 334) in Women With Hot Flashes

This study will test the hypothesis that the vasodilation associated with capsaicin-induced
dermal blood flow (DBF) provides a good model for the vasodilation associated with hot
flashes; therefore erenumab doses that cause DBF inhibition will be safe and well tolerated,
and will be effective in the reduction of the frequency and/or severity of HFs.

Inclusion Criteria:

- female subjects with hot flashes associated with menopause between 45 and 65 years of
age, inclusive, with no history or evidence of clinically relevant medical disorders
as determined by the investigator in consultation with the Amgen physician.

Exclusion Criteria:

- History or evidence of clinically significant disorder (including psychiatric),
condition or disease that, in the opinion of the Investigator or Amgen physician would
pose a risk to subject safety or interfere with the study evaluation, procedures, or
completion.